The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

363

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Psoriasis
Interventions
DRUG

Calcipotriene Foam

Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group

DRUG

Vehicle Foam

Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group

Trial Locations (26)

10029

Mt. Sinai School of Medicine Div. Dermatologic & Cosmetic Surgery, New York

14623

Dermatology Associates of Rochester, PC, Rochester

24501

Education and Research Foundation, Lynchburg

27157

Wake Forest University Health Sciences Department of Dermatology, Winston-Salem

27262

Dermatology Consulting Services, High Point

29464

Coastal Carolina Research Center, Mt. Pleasant

30078

Gwinnett Clinical Research Center, Inc., Snellville

30263

MedaPhase, Inc., Newnan

33169

Miami Dermatology Research Institute LLC, North Miami Beach

37215

Tennessee Clinical Research, Nashville

37922

The Skin Wellness Center, PC, Knoxville

40202

Dermatology Specialists, Louisville

40217

DermResearch, PLLC, Louisville

45220

Group Health Associates, Cincinnatti

48088

Grekin Skin Institute, Warren

48202

Henry Ford Medical Center, Detroit

55432

Minnesota Clinical Study Center, Fridley

63117

Central Dermatology PC, St Louis

77056

Suzanne Bruce and Associates, PA, Houston

78229

Dermatology Clinical Research Center of San Antonio, San Antonio

78759

DermReserach, Inc., Austin

80209

Cherry Creek Research, Inc., Denver

84124

Dermatology Research Center, Inc., Salt Lake City

85791

Genova Clinical Research, Tucson

92123

Therapeutics Clinical Research Center, Inc., San Diego

97223

Oregon Medical, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Stiefel, a GSK Company

INDUSTRY

NCT01139580 - The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis | Biotech Hunter | Biotech Hunter